# US 2016/0250244 A1 · Compositions for treating heartworm infestation

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0250244 A1
- Document ID: US20160250244A1
- Status: Published application
- Kind: A1
- Application number: 15/150,502
- Filed: 2016-05-10
- Published: 2016-09-01
- Earliest claimed: 2010-07-30
- Assignees: Ceva Sante Animale
- Applicants: Ceva Sante Animale
- Inventors: PATRICK FORGET; VASSILIOS KALTSATOS; STEPHAN WARIN
- Web page: https://patentgrep.com/patent/US20160250244A1

## CPC

- A61K 31/7048: having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin {, digitoxin or digoxin}
- A61K 9/0024: {Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue (compositions for intravenous administration, normal injectable solutions or dispersions for, e.g. subcutaneous administration A61K9/0019; brain implants A61K9/0085; (coated) prostheses, catheters or stents A61L)}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 33/00: Antiparasitic agents
- A61P 33/10: Anthelmintics
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention further relates to ivermectin, most preferably formulated as an implant for administration of pet and domestic animals. These formulations provide long term protection against Dirofilaria parasites, without the risks for secondary adverse events of conventional formulations. Preferred formulations are implants and are administered at least twice a year, once a year, or at least once in 18 months, up to 24 months.

## Claims

### Claim 1

A veterinary drug composition for use in controlling heartworm disease or dirofilariosis in a non-human animal subject, wherein said composition is in the form of an implant said implant releasing ivermectin sufficient to achieve and maintain plasma concentration of ivermectin in the dog between 0.1 ng/mL and 0.15 ng/mL for at least 6 months and up to 24 months after implantation.

### Claim 2 (depends on 1)

The composition of claim 1, wherein the animal subject is a pet.

### Claim 3 (depends on 2)

The composition of claim 2, wherein said pet is a canine.

### Claim 4 (depends on 1)

The composition of claim 1, wherein said composition comprises an amount of ivermectin sufficient to achieve plasma concentration in the animal subject of ivermectin in an amount of about of 0.1 ng/mL.

### Claim 5 (depends on 1)

The composition of claim 1, wherein said composition further comprises other ectoparasitic and/or endoparasitic agents and wherein, optionally, the ivermectin is replaced with a therapeutically effective amount of another avermectin.

### Claim 6

A veterinary drug composition for use in controlling Dirofilaria immitis and/or Dirofilaria repens infestation in non-human animal subject, wherein said composition is in the form of an implant, said implant releasing ivermectin sufficient to achieve and maintain plasma concentration of ivermectin in the dog between 0.1 ng/mL and 0.15 ng/mL for at least 6 months and up to 24 months after implantation.

### Claim 7 (depends on 6)

The composition of claim 6, wherein the animal subject is a pet.

### Claim 8 (depends on 7)

The composition of claim 7, wherein said pet is a canine.

### Claim 9

(canceled)

### Claim 10 (depends on 6)

The composition of claim 6, wherein said plasma concentration is about 0.1 ng/mL.

### Claim 11

A kit useful in the control of a parasitic infestation of heartworm in a non-human animal subject, which comprises an implant containing an effective dose of ivermectin for controlling Dirofilaria immitis and/or Dirofilaria repens infestation, at a lower plasma concentration of ivermectin of about 5% to 95% as compared to plasma ivermectin concentration obtained via conventional ivermectin formulation, and instructions for the treatment and/or prevention in said subject.

### Claim 12 (depends on 11)

The kit of claim 11, which further comprises other ectoparasitic and/or endoparasitic control agents and optionally a carrier.

### Claim 13 (depends on 11)

The kit of claim 11, wherein implant contains an amount of ivermectin effective to achieve and maintain a plasma ivermectin concentration of less than 0.2 ng/mL, or less to 0.15 ng/mL, or between 0.1 ng/mL to 0.15 ng/mL, or is about of 0.1 ng/mL for a period of at least 6 months, 12 months, or at least 18 months, and up to 24 months.

### Claim 14 (depends on 13)

The kit of claim 13, wherein said plasma concentration is about 0.1 ng/mL.
